Maitani Y, Igawa T, Machida Y, Nagai T
Faculty of Pharmaceutical Sciences, Hoshi University, Tokyo, Japan.
Drug Des Deliv. 1989 Mar;4(2):109-19.
Rabbits were given single doses (2 x 10(6) IU) of human fibroblast interferon (HuIFN-beta) by the following routes of administration: (a) intravenous injection, (b) dropwise intranasal administration of a liquid dosage form, and (c) spraywise intranasal administration of a powder dosage form. Following the intravenous injection, plasma HuIFN-beta concentrations declined rapidly in a biphasic manner in agreement with a two-compartment model, whilst concentrations following the intranasal administrations conformed to a one-compartment model. Maximum plasma levels and the areas under the plasma concentration-time curve (AUC) in response to dose were studied in the case of the spray administration, and found to be proportional to dose. The systemic bioavailability of HuIFN-beta (administered with sodium glycocholate and excipients) via the nasal routes was about 3% of that via the intravenous route. The elimination half-lives did not differ significantly between these two routes of administration.
通过以下给药途径给兔子单次注射(2×10⁶ IU)人成纤维细胞干扰素(HuIFN-β):(a)静脉注射,(b)滴鼻给药液体剂型,(c)喷雾给药粉末剂型。静脉注射后,血浆HuIFN-β浓度呈双相快速下降,符合二室模型,而滴鼻给药后的浓度符合一室模型。在喷雾给药情况下,研究了最大血浆水平和血浆浓度-时间曲线下面积(AUC)对剂量的反应,发现与剂量成正比。经鼻途径(与甘氨胆酸钠和辅料一起给药)的HuIFN-β全身生物利用度约为静脉途径的3%。这两种给药途径的消除半衰期无显著差异。